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Micropapillary carcinoma (MPC) of urinary tract is an uncommon variant of urothelial carcinoma with signiﬁcant diagnostic and
prognostic implications. Though MPC shows characteristic microscopic features, there exists interobserver variability and also it
needs to be diﬀerentiated from the metastasis from other organs. The prognosis is generally poor, depending on the proportion
of the micropapillary component in some reports. Early cystectomy in cases with only lamina propria invasion may be indicated
according to recent studies. This review outlines the general features of this entity and brieﬂy comments on the controversies and
the recent development.
1.Introduction
Micropapillary carcinoma (MPC) of the urinary tract is
a well-recognized variant of urothelial carcinoma (UC) char-
acterizedbydistincthistologicfeaturesandaggressiveclinical
course. Table 1 shows urothelial carcinoma and its variants
including MPC. MPC is worthy of note for its implications
regarding both diagnosis and clinical management. Despite
increased awareness of the entity and recent development
in the understanding into its pathogenesis, there still exist
controversies concerning certain aspects of this rare tumor.
This paper will outline the general features of this entity
and brieﬂy comment on the controversies and the recent
development.
2. Incidence
At least 500 cases of MPC of the bladder have been reported
as a special variant since its ﬁrst description in 1994 by
Amin et al. [1], and MPC is reported to comprise 0.6 to
8.2% of urothelial carcinoma, with later series reporting
the higher end of the spectrum [2, 3]. The recent rise in
incidence appears to reﬂect the increased awareness of this
entity, and the variable proportion occupied by this tumor
is evidently due to a lack of established criteria for diagnosis
and less-than-perfect interobserver reproducibility, both of
which issue will be addressed later in this paper. This tumor
predominantly aﬀects male with male to female ratio of 5:1
to 10:1 which is higher than that for conventional UC which
is 3:1 [1, 4–7].
3.GrossFeatures
Gross morphology of MPC is variable, and there are no
unique features to distinguish it from conventional UC
or other variants. MPC can present as papillary, sessile,
polypoid,ulcerative,orinﬁltrativemass,andthesizecanalso
be variable from microscopic focus to over 10cm [7].
4.Microscopic Features
The deﬁning microscopic feature of MPC is micropapillary
architecture reminiscent of the papillary conﬁguration seen
in ovarian papillary serous tumors. The micropapillary
pattern of MPC can present either (i) on the mucosal surface
as slender delicate processes which are usually devoid of
a ﬁbrovascular core and appear as glomeruloid bodies on2 Advances in Urology
Table 1: Urothelial carcinoma and its variants.
Inﬁltrating urothelial carcinoma with squamous diﬀerentiation
Inﬁltrating urothelial carcinoma with glandular diﬀerentiation









Figure 1: The MPC (left) shows delicate ﬁliform projections on
the mucosal surface, diﬀerent from the ordinary type of papillary
carcinoma (right).
cross section (Figure 1), or (ii) in the invasive component
as small tight cell nests or balls contained in lacunae or
stromal retraction spaces (Figure 2), mimicking lymphovas-
cular invasion (LVI). The nuclei of tumor cells are frequently
of high grade, showing reversed polarity to the external
surface of tumor nests (Figure 3). A small proportion of the
tumor-containing spaces represents actual lymphovascular
invasion as evidenced by immunostaining for endothelial
markers such as factor VIIIR-Ag, Ulex europaeus agglutinin
I lectin, CD 31, CD34, and D2-40 (Figure 4). Although
LVI is present in most cases of invasive MPC if adequately
sampled and diligently searched for, a vast majority of
the tumor-containing lacunae lack endothelial lining and
do not constitute true LVI. Psammoma bodies, found in
ovarian papillary serous neoplasia, are vanishingly rare in
urinary tract MPC. The overwhelming majority of this
tumor shows deep muscle invasion (Figure 5), and thus, it
is recommended to alert clinicians regarding the invasive
potential of this tumor when the biopsy is obtained mainly
from the superﬁcial layer and proper muscle is not included
in the biopsy [1, 8].
MPC is usually accompanied by conventional UC, the
proportion of MPC ranging from focal to almost exclusive.
Figure 2: Deep invasive component of MPC displays tight nests or
balls of tumor cells in lacuna-like spaces.
Figure 3: The tumor cells show high nuclear grade and reversed
polarity.
There are no established criteria for the cutoﬀ proportion
of MP component to qualify as MPC and some authors
suggest 5% or 10% as the lower limit, while others adopt
a noncommittal approach and render diagnosis using ter-
minology such as “UC, high grade, with micropapillary
histology (40%)” [9]. It is reported that the presence of
any amount of MPC portends a poor outcome [5] and that
a larger proportion of MP component is associated with
more dismal clinical outcome [10]. Therefore, whichever
criteria one may apply for the deﬁnition of MPC, it is
recommended to report the presence and the proportion of
MP component in the pathology report. MPC is frequently
accompanied by in situ carcinoma, and coexistence has been
reportedwithadenocarcinoma[11,12],smallc ellcar cino ma
[12], sarcomatoid carcinoma [13], pleomorphic giant cell
carcinoma [14], lipoid variant [15], or plasmacytoid variant
of UC [16].
On urine cytology, the smear shows papillary/spheroid
clusters of tumor cells showing a high nuclear grade. Solitary
tumor cells are infrequent and the background is relatively
clear, reﬂecting the growth pattern of the tumor which is
usually transmural rather than superﬁcial spread [17].Advances in Urology 3
Figure 4: Immunostaining for D2-40 demonstrates a focus of lym-
phatic invasion. This stain proves that the bulk of clear lacunar
spaces are not true lymphovascular spaces.




The most important diﬀerential diagnosis for urinary tract
MPCisitsdistinctionfromconventionalUCwithprominent
retraction artifacts, which issue has been elegantly addressed
in a recent consensus study by Sangoi et al. [6]. In that study,
the agreement among uropathologists for the diagnosis of
MPC was only moderate and the authors provide a few
diagnostically useful morphologic observations. In their
opinion, whichis shared by us, multiple or small tumornests
in lacunar spaces are important diagnostic clues, while large
or branching nests with anastomoses and conﬂuence argue
against the diagnosis of MPC. In this context, it appears that
a sizable proportion of disagreement is from cases which dis-
play an intimate mixture of tumor nests displaying variable-
sized tumor nests in diverse conﬁguration. We suggest that
it would be reasonable to diagnose MPC only when there
is at least one high-power-ﬁeld area of pure classic MPC
without readily identiﬁable contradicting features. There are
no immunohistochemical markers to reliably diﬀerentiate
MPC from conventional UC. Though it has been reported
that MUC1, CA125, Her/neu, and KL-6 might be speciﬁc for
MPC [18], these results were not supported by other studies
[19].
The next critical issue is the diﬀerential diagnosis from
MPC of other organs in a metastatic setting. For example,
in female patients presenting with abdominal metastasis,
the main diﬀerential diagnosis is with metastatic papil-
lary serous carcinoma of the ovary or primary peritoneal
serous carcinoma. Clinical and radiologic correlation is
mandatory, but there are a few helpful histologic and
immunohistochemical features, such as the presence of
typical UC or immunoreactivity to CK 20, high molecular
weight cytokeratin, thrombomodulin, and uroplakin III in
MPC of the bladder. Although uncommon, there also exist
clinical situations where it is necessary to rule out metastatic
MPC from other organs such as the lung, breast, pancreas,
colon, stomach, or salivary glands. In such cases, the best
immunohistochemistrypaneliscombininguroplakinIIIand
CK20 (bladder), CK20 and CDX2 (colon), TTF-1 (lung), ER
and mammaglobin (breast), and WT-1 and PAX8 (ovary)
which can diﬀerentiate between primary cancers of urinary
tract, lung, breast, ovary, and colon though pancreas and
salivary gland are left with no speciﬁc markers [20].
6. Pathogenesis andMolecularChanges of MPC
There is a paucity of data regarding the pathogenesis of
MPC.However,oneinterestingaspectisthereversedpolarity
of tumor cells. With that, tumor cells facing the stroma
acquire apical secretory properties evidenced by ultrastruc-
tural examination and immunostaining for MUC1, a surface
glycoprotein present on the apical/luminal surface. This
unusual interface might lead to the detachment of tumor
cells from the stroma, facilitating stromal invasion [21].
Some authors suggest that MPC may represent a form
of glandular diﬀerentiation based on immunoreactivity to
CA125 [10], and this appears to be a plausible argument,
considering that MPC found in other organs is mostly a
variant of adenocarcinoma. However, occasional expression
of CA 125 in conventional UC, usual coexistence with
conventional UC and rare expression of other markers of
glandulardiﬀerentiationsuchasMUC5A,MUC6,andCDX2
suggests that MPC of the bladder is of urothelial origin [22].
Another characteristic ﬁnding of MPC is the overexpres-
sion of Aurora A compared to conventional UC. Aurora
A is a key player in maintaining genomic integrity, and
its expression is associated with poor clinical outcome in
bladder cancer. Enhanced expression of Aurora A may be a
mechanism underlying increased chromosome copy number
and total nuclear DNA content, contributing to the clinical
aggressiveness of MPC [23].
On the level of molecular alterations, one early study
has reported that p53 abnormalities are rare in MPC as
compared to conventional UC, while the ﬁndings are the
opposite for H-ras [24]. This implies distinct molecular
pathways for MPC, but the number of cases was too small
for generalization, and there has been no additional study to
consolidate these ﬁndings.4 Advances in Urology
7.Treatment andClinicalCourse
Both clinical and pathological implication has undoubtedly
contributed to the establishment of MPC as a distinct entity
along with its wide recognition. Clinically, this tumor is
almost invariably muscle invasive at the time of presentation
with frequent metastasis to lymph nodes and distant organs.
Thus, it is imperative to get a deep biopsy when the proper
muscle invasion is not found on superﬁcial sampling.
Conventional paradigm for treatment of UC is imple-
menting radical surgery in the muscle invasive diseases and
intravesical BCG administration for the nonmuscle-invasive
cases. While the conventional approach is applied in most
institutions, early cystectomy for the nonmuscle-invasive
MPC is advocated by one leading group on the ground
that these tumors eventually develop muscle invasion and
that the response to chemotherapy is limited when used
as a secondary modality. Kamat et al. from MD Anderson
CancerCenterreporteda10-yearsurvivalrateof72%among
patients who received early cystectomy for the nonmuscle-
invasive disease, while none survived after the treatment
according to the conventional paradigm [4]. Generally,
clinical course is mostly poor with the 5-year and 10-year
overall survival rates in the largest study being 74 and 54%,
respectively [4].
Aggressive clinical behavior and the diﬀerent treatment
modality of MPC from other forms of UC illustrate the
importance of correct recognition of MPC and the diﬀer-
ential diagnosis of MPC from UC with tumor cells within
artifactual tissue spaces, mimicking MPC.
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